IMPORTANT SAFETY INFORMATION AND INDICATION
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
The most common adverse reaction occurring in ≥1% of subjects in clinical trials was application site pain, such as burning or stinging.
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older.
Reference: 1. EUCRISA® (crisaborole) Full Prescribing Information. October 2017.
Please see Full Prescribing Information.
PP-CRI-USA-1162 © 2018 Pfizer Inc.
All rights reserved. April 2018
For the treatment of mild-to-moderate atopic dermatitis in patients 2 and older
For topical use only. Not for ophthalmic, oral, or intravaginal use.
the face and body1
EUCRISA can be applied to the
skin anywhere on
Please see adjacent
IMPORTANT SAFETY INFORMATION and INDICATION.
Choose steroid-free EUCRISA, the first and only topical PDE4 inhibitor.1
The specific mechanism(s) of action of crisaborole
in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4.